Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded

AIDS Research and Human Retroviruses

Volumn 20, Issue 3, 2004, Pages 285-295

  Swiggard, William J ^a   O'Doherty, Una ^a   McGain, David ^a   Jeyakumar, Deepa ^a   Malim, Michael H ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; VIRUS DNA; VIRUS RNA;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL LINE; DNA, COMPLEMENTARY; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; TRANSCRIPTION, GENETIC; VIRION; VIRUS LATENCY;

EID: 1842554843     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204322996527     Document Type: Article

References (67)

1. Schnittman SM, Psallidopoulos MC, Lane HC, et al.: The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:305-308.
2. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
3. Chun T-W, Finzi D, Margolick J, Chadwick K, Schwartz D, and Siliciano RF: In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1995;1:1284-1290.
4. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
5. Chun T-W, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188.
6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, and Fauci AS: Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-8873.
7. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
8. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
9. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
10. Zhang Z-Q, Schuler T, Zupancic M, et al.: Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286:1353-1357.
11. Schrager LK and D'Souza MP: Cellular and anatomic reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998;280:67-71.
12. Chun TW and Fauci AS: Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999;96:10958-10961.
13. Pierson T, McArthur J, and Siliciano RF: Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000;18:665-708.
14. Blankson JN, Persaud D, and Siliciano RF: The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-593.
15. van Rij RP, Visser JA, van Praag ME, et al.: Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J Virol 2002;76:3054-3058.
16. Pomerantz RJ: Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication. Clin Infect Dis 2002;34:91-97.
17. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat Med 2003;9:727-728.
18. Lori F, Jessen H, Lieberman J, et al.: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999;180:1827-1832.
19. Strain MC, Little SJ, Daar ES, et al.: Initiation of treatment before seroconversion increases the rate of clearance of the latent reservoir. Oral abstract and presentation. 97. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
20. Ramratnam B, Mittler JE, Zhang L, et al.: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000;6:82-85.
21. Chun T-W, Engel D, Mizell SB, et al.: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-655.
22. Dybul M, Hidalgo B, Chun T-W, et al.: Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002;185:61-68.
23. Prins JM, Jurriaans S, van Praag RM, et al.: Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999;13:2405-2410.
24. van Praag RM, Prins JM, Roos MT, et al.: OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001;21:218-226.
25. Pomerantz RJ, Otero M, Nunnari G, et al.: Residual HIV-1 Disease Eradication (RHIDE) Trial: An HIV-1 eradication approach in humans using a novel and stimulatory intensification therapy. Poster 405-T. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
26. Stellbrink HJ, van Lunzen J, Westby M, et al.: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002;16:1479-1487.
27. Brooks DG, Kitchen SG, Kitchen CMR, Scripture-Adams DD, and Zack JA: Generation of HIV latency during thymopoiesis. Nat Med 2001;7:459-464.
28. Shen A, Zink MC, Mankowski JL, et al.: Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003;77:4938-4949.
29. Eckstein DA, Penn ML, Korin YD, et al.: HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001;15:671-682.
30. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen ISY: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
31. Stevenson M, Stanwick TL, Dempsey MP, and Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO 1990;9:1551-1560.
32. Spina CA, Guatelli JC, and Richman DD: Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995;69:2877-2988.
33. Tang S, Patterson BK, and Levy JA: Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol 1995;69:5659-5665.
34. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188.
35. O'Doherty U, Peng M, Gezelter S, et al.: Human blood contains two subsets of dendritic cells, one immunologically mature, and the other immature. Immunology 1994;82:487-493.
36. O'Doherty U, Steinman RM, Peng M, et al.: Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocytes-conditioned medium. J Exp Med 1993;178:1067-1078.
37. Steinman RM, Inaba K, Turley S, Pierre P, and Mellman I: Antigen capture, processing, and presentation by dendritic cells: Recent cell biological studies. Hum Immunol 1999;60:562-567.
38. Zack JA, Haislip AM, Krogstad P, and Chen ISY: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
39. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998;72:3161-3168.
40. 0 lymphocytes. J Virol 1999;73:6526-6532.
41. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, and Siliciano RF: Molecular characterization of preintegration latency in HIV-1 infection. J Virol 2002;76:8518-8531.
42. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al.: Macrophage-tropic variants initiate human immunodeficiency virus infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-2067.
43. Pierson T, Hoffman TL, Blankson J, et al.: Characterization of chemokine receptor utilization of viruses in the latent reservoir for Human Immunodeficiency Virus Type-1. J Virol 2000;74:7824-7833.
44. Nara PL, Hatch WC, Dunlop NM, et al.: Simple, rapid quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 1987;3:283-302.
45. Clouse KA, Powell D, Washington I, et al.: Monokine regulation of HIV-1 expression in a chronically infected human T-cell clone. J Immunol 1989;142:431-438.
46. Li Y, Hui H, Burgess CJ, et al.: Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation. J Virol 1992;66:6587-6600.
47. Li Y, Kappes JC, Conway JA, Price RW, Shaw GH, and Hahn BH: Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. J Virol 1991;65:3973-3985.
48. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, and Malim MH: HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO 1997;16:4531-4539.
49. O'Doherty U, Swiggard WJ, and Malim MH: Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000;74:10074-10080.
50. Tyagi S and Kramer FR: Molecular beacons: Probes that fluoresce upon hybridization. Nat Biotechnol 1996;14:303-308.
51. Toba K, Winton EF, Koike T, and Shibata A: Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J Immunol Methods 1995;182:193-207.
52. Zagury D, Bernard J, Leonard R, et al.: Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-853.
53. Folks T, Kelly J, Benn S, et al.: Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986;136:4049-4053.
54. Mackay CR: Migration pathways and immunologic memory among T lymphocytes. Semin Immunol 1992;4:51-58.
55. Kim S, Ikeuchi K, Groopman J, and Baltimore D: Factors affecting cellular tropism of human immunodeficiency virus. J Virol 1990;64:5600-5604.
56. Butler SL, Hansen MST, and Bushman FD: A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-634.
57. Weissman D, Daucher J, Barker T, Adelsberger J, Baseler M, and Fauci AS: Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions. Adv Exp Med Biol 1996;12:759-767.
58. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, and Fauci AS: The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. J Infect Dis 1998;177:1332-1338.
59. Unutmaz D, KewalRamani VN, Marmon S, and Littman DR: Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 1999;189:1735-1746.
60. Chun TW, Engel D, Mizell SB, Ehler LA, and Fauci AS: Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998;188:83-91.
61. Scripture-Adams DD, Brooks DG, Korin YD, and Zack JA: Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76:13077-13082.
62. Chun TW, Justement JS, Lempicki RA, et al.: Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003;100:1908-1913.
63. Sheehy AM, Gaddis NC, Choi JD, and Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418:646-650.
64. Harris RS, Bishop KN, Sheehy AM, et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 2003;113:803-809.
65. Harris RS, Sheehy AM, Craig HM, Malim MH, and Neuberger MS: DNA deamination: Not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 2003;4:641-643.
66. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, and Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003 (letter to Nature published online in advance of publication, reference doi:10.1038/nature01707).
67. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, and Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003 (letter to Nature published online in advance of publication, reference doi:10.1038/nature01709).